Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Debt Repayments: 2015-2019

Historic Long-Term Debt Repayments for Lineage Cell Therapeutics (LCTX) over the last 2 years, with Jun 2019 value amounting to $18,000.

  • Lineage Cell Therapeutics' Long-Term Debt Repayments fell 66.67% to $18,000 in Q2 2019 from the same period last year, while for Jun 2019 it was $74,000, marking a year-over-year decrease of 79.15%. This contributed to the annual value of $70,000 for FY2019, which is 30.69% down from last year.
  • According to the latest figures from Q2 2019, Lineage Cell Therapeutics' Long-Term Debt Repayments is $18,000, which was down 65.38% from $52,000 recorded in Q1 2019.
  • Lineage Cell Therapeutics' Long-Term Debt Repayments' 5-year high stood at $173,000 during Q4 2017, with a 5-year trough of -$50,000 in Q3 2018.
  • Its 3-year average for Long-Term Debt Repayments is $53,571, with a median of $52,000 in 2019.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first skyrocketed by 321.95% in 2017, then crashed by 66.67% in 2019.
  • Over the past 5 years, Lineage Cell Therapeutics' Long-Term Debt Repayments (Quarterly) stood at $28,000 in 2015, then skyrocketed by 46.43% to $41,000 in 2016, then surged by 321.95% to $173,000 in 2017, then soared by 212.90% to -$50,000 in 2018, then tumbled by 66.67% to $18,000 in 2019.
  • Its Long-Term Debt Repayments stands at $18,000 for Q2 2019, versus $52,000 for Q1 2019 and -$50,000 for Q3 2018.